Eli Lilly agrees to pay $57 a share for Morphic, a 79% premium to the stock’s closing price of $31.84 on Friday.

Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced ...

Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the ...

Eli Lilly acquires Morphic Holding for $3.2 billion, gaining a potential IBD treatment asset, MORF-057. Explore more details ...

(Bloomberg) — Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some ...

Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda ...

Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...

In a landmark deal poised to reshape the landscape of chronic disease treatment, pharmaceutical giant Eli Lilly and Company ...

The acquisition bolsters Lilly's gastroenterology portfolio, with a focus on developing new treatments for inflammatory bowel ...

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's ...

Eli Lilly & Co. acordó comprar Morphic Holding Inc., fabricante estadounidense de fármacos para el intestino, por alrededor ...

Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease.